Playback speed
10 seconds
2021 ADA Highlights: Landmark DAPA-CKD Trial in Kidney Disease: Extending the Benefits of SGLT2 Inhibitors to and Beyond Diabetic Neuropathy
370 views
July 14, 2021
Comments 0
Login to view comments.
Click here to Login